Program
BL1332
A development code. Also written as “Topical Ocular BL1332 low dose”, “Topical Ocular BL1332 high dose” and “BL1332 eye drops”.
Its studies are mostly in Pain, Postoperative · Eye Pain, led by Bausch Health Companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 31 open or running | phase 2since Jan 26, 2026 | May 8, 2025 | Nov 2026phase 1 · NCT06978244 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2025First study: phase 1 study in Eye PainFirst studyNCT06978244 · 24 enrolled · United States
- Jan 26, 2026Phase 2 study in Pain, PostoperativePhase 2 reachedNCT07412496 · 130 enrolled · United States
- Jul 16, 2026Phase 1 study in HealthyNCT07717918 · 28 enrolled · United States
Ahead
- Nov 2026Primary completion: phase 1 study in Eye PainNCT06978244
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07717918Healthy · United States | 1 | Completed | Aug 5, 2026 | 28 |
| NCT07412496Pain, Postoperative · United States | 2 | Completed | Oct 4, 2026 | 130 |
| NCT06978244Eye Pain · United States | 1 | Active, not recruiting | Nov 2026 | 24 |
How it is read
Names in the registry
- “Topical Ocular BL1332 low dose”, 1 entry
- “Topical Ocular BL1332 high dose”, 1 entry
- “BL1332 eye drops”, 1 entry
- “BL1332 ophthalmic solution”, 1 entry
Codes read as this program: BL1332.
Conditions, from the studies’ own filings
- Pain, Postoperative, 1 study
- Eye Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.